



MEETING ABSTRACT

Open Access

## OR10-004 - Circulating micrnas in TRAPS

OM Lucherini<sup>1\*</sup>, L Obici<sup>2</sup>, M Ferracin<sup>3</sup>, V Fulci<sup>4</sup>, MF McDermott<sup>5</sup>, G Merlini<sup>6</sup>, I Muscari<sup>7</sup>, F Magnotti<sup>1</sup>, LJ Dickie<sup>5</sup>, M Galeazzi<sup>7</sup>, M Negrini<sup>3</sup>, CT Baldari<sup>8</sup>, R Cimaz<sup>9</sup>, L Cantarini<sup>10</sup>

From 7th Congress of International Society of Systemic Auto-Inflammatory Diseases (ISSAID) Lausanne, Switzerland. 22-26 May 2013

### Introduction

To the best of our knowledge circulating miRNAs in TRAPS, as well as in other monogenic autoinflammatory disorders have never been investigated.

### Objectives

To evaluate circulating microRNAs (miRNAs) levels in patients with tumor necrosis factor-receptor associated periodic syndrome (TRAPS), in comparison to healthy controls, and to correlate their levels to parameters of disease activity and/or disease severity.

### Methods

Expression levels of circulating miRNAs were measured by Agilent microarrays in 29 serum samples from 15 TRAPS patients carrying mutations known to be associated with high disease penetrance and 8 healthy controls. Differentially expressed and clinically relevant miRNAs were detected using GeneSpring GX software.

### Results

We identified a 6 miRNAs signature able to discriminate TRAPS from healthy controls. Moreover, 4 miRNAs were differentially expressed between patients treated with the interleukin (IL)-1 receptor antagonist anakinra and untreated patients. Of these, miR-92a-3p expression was found to be reduced in untreated patients, while its expression levels were similar to healthy controls in samples obtained during anakinra treatment. MiR-92b levels were inversely correlated with the number of fever attacks/year during the 1<sup>st</sup> year from the index attack of TRAPS, while miR-377-5p levels were positively correlated with serum amyloid A (SAA) circulating levels.

### Conclusion

Serum miRNAs levels show a baseline pattern in TRAPS, and may serve as potential markers of response to therapeutic intervention.

### Competing interests

None declared.

### Authors' details

<sup>1</sup>Department of Medical Sciences, Surgical and Neuroscience. Rheumatology Unit, Università di Siena, Siena, Italy. <sup>2</sup>Amyloid Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, Italy. <sup>3</sup>Laboratory for Technologies of Advanced Therapies (LTTA) and Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy. <sup>4</sup>Dipartimento di Biotecnologie Cellulari ed Ematologia, Sezione di Genetica Molecolare, Sapienza, Università di Roma, Roma, Italy. <sup>5</sup>NIHR-Leeds Musculoskeletal Biomedical Research Unit (NIHR-LMBRU), Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK. <sup>6</sup>University of Pavia, Pavia, Italy. <sup>7</sup>Università di Siena, Siena, Italy. <sup>8</sup>Department of Life Sciences, Università di Siena, Siena, Italy. <sup>9</sup>Department of Pediatrics, Rheumatology Unit, Anna Meyer Children's Hospital and University of Florence, Florence, Italy. <sup>10</sup>Department of Medical Sciences, Surgical and Neuroscience. Rheumatology Unit, University of Siena, Siena, Italy.

Published: 8 November 2013

doi:10.1186/1546-0096-11-S1-A187

Cite this article as: Lucherini et al.: OR10-004 - Circulating micrnas in TRAPS. *Pediatric Rheumatology* 2013 **11**(Suppl 1):A187.

<sup>1</sup>Department of Medical Sciences, Surgical and Neuroscience. Rheumatology Unit, Università di Siena, Siena, Italy

Full list of author information is available at the end of the article